Q2 FY27 revenue up 21%, consolidated net profit up 11%, standalone net profit up 42%
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.6 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sudeep Pharma's Q2 FY27 consolidated revenue was Rs 196.70 crore, up 21% from Rs 162.67 crore, and net profit rose 11% to Rs 51.81 crore. Standalone net profit jumped 42% to Rs 42.34 crore. For the half year, consolidated revenue rose 23% to Rs 354.97 crore and net profit rose 18% to Rs 92.40 crore. Operating cash flow was positive at Rs 43.50 crore. The auditor gave an unmodified review; one subsidiary was not reviewed but is not material.
Strong sales and profit growth plus healthy cash flow should support the stock, though specialty ingredient sales fell and borrowings rose.